Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 5775-5782

  Zhong, Wenlong ^a,b,c   Zhang, Lei ^a,b,c   Ma, Jiajian ^d   Shao, Shan ^b   Lin, Rongcheng ^a,b,c   Li, Xuesong ^a,b,c   Xiong, Gengyan ^a,b,c   Fang, Dong ^a,b,c   Zhou, Liqun ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c NATIONAL UROLOGICAL CANCER CENTER   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Aristolochic acid; Prognosis; Radical nephroureterectomy; Survival; Upper urinary tract; Urothelial carcinoma

Indexed keywords

ARISTOLOCHIC ACID;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CHINA; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; RADICAL NEPHRECTOMY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME;

EID: 85037734328     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S148641     Document Type: Article

References (23)

1. Roupret M, Babjuk M, Comperat E, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015;68(5):868–879.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
3. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–1233.
4. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–1692.
5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002;82:1–556.
6. Wu F, Wang T. Risk assessment of upper tract urothelial carcinoma related to aristolochic acid. Cancer Epidemiol. 2013;22(5):812–820.
7. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158–169.
8. Jelakovic B, Karanovic S, Vukovic-Lela I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012;81(6):559–567.
9. Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012;109(21):8241–8246.
10. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–186.
11. Cukuranovic R, Ignjatovic I, Visnjic M, et al. Characteristics of upper urothelial carcinoma in an area of Balkan endemic nephropathy in south Serbia. A fifty-year retrospective study. Tumori. 2010;96(5):674–679.
12. Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14s–20s.
13. National Pharmacopoeia Committee. The Pharmacopoeia of People’s Republic of China. 1st ed. Beijing: Chemical Industry Press; 2000.
14. China Food and Drug Administration. Notice on the cancellation of the medicinal use of Guan Mu Tong, No. 121. [in Chinese] Available from: http://www.sda.gov.cn/WS01/CL0844/9977.html. Accessed April 1, 2003.
15. China Food and Drug Administration. Notice on Strengthening the Supervision and Management on the Use and Production of Guang Fangchi and Five Other Herbs, No. 379. [in Chinese] Available from: http://www.sda.gov.cn/WS01/CL0844/10242.html. Accessed August 5, 2004.
16. Zhang L, Xiong G, Fang D, et al. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation. J Exp Clin Cancer Res. 2015;34:5.
17. Lemy A, Wissing KM, Rorive S, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis. 2008;51(3):471–477.
18. Lughezzani G, Sun M, Perrotte P, et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology. 2010;75(2):321–327.
19. Chen XP, Xiong GY, Li XS, et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int. 2013;112(7):917–924.
20. Chen CH, Dickman KG, Huang CY, et al. Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. Oncotarget. 2016;7(29):45225–45236.
21. Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol. 2004;172(3):1127–1129.
22. Fang D, Liu P, Li X, et al. Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients. Sci Rep. 2015;5:18014.
23. Li WH, Yang L, Su T, Song Y, Li XM. [Influence of taking aristolochic acid-containing Chinese drugs on occurrence of urinary transitional cell cancer in uremic uremic patients undergoing dialysis]. Zhonghua Yi Xue Za Zhi. 2005;85(35):2487–2491. Chinese.